

# Chau T Dang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10000296/publications.pdf>

Version: 2024-02-01

59  
papers

4,540  
citations

201674

27  
h-index

149698

56  
g-index

59  
all docs

59  
docs citations

59  
times ranked

6617  
citing authors

#	ARTICLE	IF	CITATIONS
1	Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 117-124.	0.8	11
2	Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 16.	5.2	15
3	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. <i>Npj Breast Cancer</i> , 2022, 8, 18.	5.2	8
4	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. <i>Npj Breast Cancer</i> , 2022, 8, 37.	5.2	9
5	BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. <i>Cancers</i> , 2022, 14, 2596.	3.7	8
6	Racial and Socioeconomic Disparities in Cardiotoxicity Among Women With HER2-Positive Breast Cancer. <i>American Journal of Cardiology</i> , 2021, 147, 116-121.	1.6	23
7	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2375-2385.	1.6	76
8	Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With HER2/CEP17 Ratio $\leq 2.0$ and Average HER2 Copy Number $\geq 4.0$ and $\leq 6.0$ . <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 597-601.	2.5	10
9	Early Trastuzumab Interruption and Recurrence-Free Survival in <i>ERBB2</i> -Positive Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1971.	7.1	20
10	Cardiotoxicity Surveillance and Risk of Heart Failure During HER2 Targeted Therapy. <i>JACC: CardioOncology</i> , 2020, 2, 166-175.	4.0	17
11	Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of <i>ERBB2</i> -Positive Breast Cancer. <i>JAMA Cardiology</i> , 2020, 5, 309.	6.1	46
12	Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 452-478.	4.9	848
13	Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. <i>Oncologist</i> , 2019, 24, e646-e652.	3.7	5
14	Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 61-66.	2.5	42
15	Assessment of Early Radiation-Induced Changes in Left Ventricular Function by Myocardial Strain Imaging After Breast Radiation Therapy. <i>Journal of the American Society of Echocardiography</i> , 2019, 32, 521-528.	2.8	30
16	Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1868-1875.	1.6	229
17	Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 239-246.	2.5	26
18	Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. <i>JAMA Network Open</i> , 2019, 2, e1916211.	5.9	7

#	ARTICLE	IF	CITATIONS
19	Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 387-394.	2.4	37
20	Efficacy of Exercise Therapy on Cardiorespiratory Fitness in Patients With Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2018, 36, 2297-2305.	1.6	223
21	Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node–Positive and High-Risk Lymph Node–Negative Breast Cancer (E5103). <i>Journal of Clinical Oncology</i> , 2018, 36, 2621-2629.	1.6	52
22	In Reply. <i>Oncologist</i> , 2018, 23, e165-e166.	3.7	0
23	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. <i>Cancer Cell</i> , 2018, 34, 427-438.e6.	16.8	633
24	Overview of Breast Cancer Therapy. <i>PET Clinics</i> , 2018, 13, 339-354.	3.0	279
25	Left Ventricular Ejection Fraction Monitoring Adherence Rates. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1094-1097.	5.3	3
26	Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor–Positive Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1700.	7.1	151
27	Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. <i>Oncologist</i> , 2017, 22, 139-143.	3.7	27
28	SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. <i>Oncologist</i> , 2017, 22, 518-525.	3.7	31
29	Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer. <i>Oncologist</i> , 2017, 22, 642-647.	3.7	30
30	Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 241-247.	2.5	16
31	Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer. <i>Oncologist</i> , 2016, 21, 418-424.	3.7	46
32	Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis. <i>Clinical Breast Cancer</i> , 2016, 16, e69-e74.	2.4	7
33	A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 87-94.	2.4	1
34	Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter. <i>Journal of Clinical Oncology</i> , 2016, 34, 1030-1033.	1.6	82
35	Initial Results of a Prospective Clinical Trial of <sup>18</sup> F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1350-1356.	5.0	60
36	Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 29.	7.1	68

#	ARTICLE	IF	CITATIONS
37	Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 134-141.	27.0	598
38	The Development of Dose-Dense Adjuvant Chemotherapy. <i>Breast Journal</i> , 2015, 21, 42-51.	1.0	12
39	Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 442-447.	1.6	75
40	Feasibility and Cardiac Safety of Trastuzumab Emtansine After Anthracycline-Based Chemotherapy As (neo)Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1136-1142.	1.6	67
41	Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction. <i>Oncologist</i> , 2015, 20, 1105-1110.	3.7	26
42	Dual Targeting of Human Epidermal Growth Factor Receptor 2 (HER2) in Neoadjuvant Trials for Operable HER2 Positive (HER2+) Disease. <i>Current Breast Cancer Reports</i> , 2013, 5, 321-330.	1.0	2
43	Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. <i>Cancer</i> , 2013, 119, 3943-3951.	4.1	18
44	Epirubicin: Is it like doxorubicin in breast cancer? A clinical review. <i>Breast</i> , 2012, 21, 142-149.	2.2	151
45	Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib. <i>Clinical Cancer Research</i> , 2011, 17, 3490-3499.	7.0	131
46	Dose-Dense Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel With Trastuzumab and Lapatinib in HER2-Overexpressed/Amplified Breast Cancer Is Not Feasible Because of Excessive Diarrhea. <i>Journal of Clinical Oncology</i> , 2010, 28, 2982-2988.	1.6	40
47	Dose-Dense Adjuvant Doxorubicin and Cyclophosphamide Is Not Associated With Frequent Short-Term Changes in Left Ventricular Ejection Fraction. <i>Journal of Clinical Oncology</i> , 2009, 27, 6117-6123.	1.6	26
48	Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. <i>Current Breast Cancer Reports</i> , 2009, 1, 1-2.	1.0	3
49	The role of adjuvant anthracyclines for breast cancer treatment: Can we use molecular predictors?. <i>Current Breast Cancer Reports</i> , 2009, 1, 5-11.	1.0	0
50	Prolonged Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel in Breast Cancer Is Feasible. <i>Clinical Breast Cancer</i> , 2008, 8, 418-424.	2.4	12
51	Dose-Dense Chemotherapy With Trastuzumab Is an Appropriate Option. <i>Journal of Clinical Oncology</i> , 2008, 26, 3655-3656.	1.6	2
52	The Safety of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Trastuzumab in HER2-Overexpressed/Amplified Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1216-1222.	1.6	56
53	Adjuvant Taxanes in the Treatment of Breast Cancer: No Longer at the Tip of the Iceberg. <i>Clinical Breast Cancer</i> , 2006, 7, 51-58.	2.4	21
54	Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 427-436.	2.4	12

#	ARTICLE	IF	CITATIONS
55	Phase II Study of Feasibility of Dose-Dense FEC Followed by Alternating Weekly Taxanes in High-Risk, Four or More Node-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 5754-5761.	7.0	31
56	Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments. <i>Clinical Cancer Research</i> , 2004, 10, 4062-4067.	7.0	61
57	Dose-dense treatment prolongs disease-free survival of women with node positive breast cancer. <i>Cancer Treatment Reviews</i> , 2003, 29, 453-456.	7.7	0
58	Risk models for neutropenia in patients with breast cancer. <i>Oncology</i> , 2003, 17, 14-20.	0.5	2
59	Potential role of selective COX-2 inhibitors in cancer management. <i>Oncology</i> , 2002, 16, 30-6.	0.5	18